Japan's pharmaceutical sector remains weak in the short term; watch for a rebound window driven by 2H 2026 catalysts

Overview

This report is JPMorgan's weekly update on Japan's pharmaceutical sector, covering share-price performance during June 15-19, major company events, valuation tables, event and catalyst calendars, academic conference schedules, infectious disease data, US TRx prescription trends for major drugs, and foreign-exchange sensitivity. The core conclusion is that the sector may remain weak in the short term, but some share prices could recover as April-June results are reported and clinical, regulatory, and product events unfold in 2H 2026.

Core views

The report believes that although both Japan and the US had monetary-policy events and the Nikkei Average reached a record high on June 19, indicating a recovery in risk appetite, buying was concentrated mainly in AI and semiconductor stocks, leaving the pharmaceutical sector significantly behind. Kyowa Kirin and Sumitomo Pharma led weekly performance; Kyowa Kirin was the sector's best performer over the past month. The report believes medium- to long-term uncertainty remains following the termination of rocatinlimab development, but the bad news may already be fully reflected in the short term. Key areas to watch are the results of Kyowa Kirin's Phase 2 KHK4951 study and confirmation in 2Q results of the possibility of data disclosure at an academic conference in October.

Analysis framework

The report uses a multidimensional monitoring framework covering sector relative returns, company share-price performance over various periods, domestic and overseas pharmaceutical valuations, event and catalyst calendars, academic conference schedules, drug TRx prescription trends, and foreign-exchange sensitivity to assess Japan's pharmaceutical sector relative to TOPIX and other industries and identify clinical, regulatory, litigation, and commercialization events that could affect individual stocks.

Methodology notes

• Relative Performance AnalysisComparison of Sector and Individual-Stock Returns over Different Periods

  Compare the pharmaceutical sector and major companies with TOPIX and other industries over 1-week, 1-month, 3-month, 6-month, and YTD periods.

  This method is used to determine whether the pharmaceutical sector is attracting market capital and whether individual-stock performance shows relative-strength signals.

• Catalyst TrackingEvent and Catalyst Calendar

  Track 2Q results, clinical data, regulatory approvals, academic conferences, and company announcements.

  The report believes the sector may remain weak in the short term, but catalysts in 2H 2026 could become key points to watch for share-price appreciation.

• Fundamental TrackingUS Prescription TRx Monitoring

  Track changes in prescription volumes for major drugs from Japanese pharmaceutical companies in the US market.

  TRx data can be used to observe drug commercialization trends, the competitive landscape, and revenue momentum.

• Risk SensitivityForeign-Exchange Sensitivity Analysis

  Assess the impact of exchange-rate changes on core operating profit, business profit, or earnings per share.

  Japanese pharmaceutical companies have globalized revenue and cost structures, so exchange-rate fluctuations may affect earnings forecasts.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Japan Pharmaceutical Sector

  Core research subject

  Strengths

  Has multiple upcoming catalysts, including 2Q results, clinical readouts, regulatory approvals, and drug prescription trends.

  Weaknesses

  Has recently significantly underperformed TOPIX, while capital preferences have concentrated on AI and semiconductors, leaving sector momentum insufficient.

  Comparison

  The pharmaceutical sector rose +0.8% during June 15-19 versus TOPIX at +4.2%; over three months, the pharmaceutical sector was -11.1% versus TOPIX at +12.1%.

  Risks

  A continued market tilt toward high-beta growth sectors, disappointing clinical data, approval delays, and foreign-exchange disruptions.

• Kyowa Kirin (4151)

  Key individual stock to monitor

  Strengths

  The sector's best performer over the past month and rose 5.7% for the week; the bad news may have been absorbed by the market in the short term.

  Weaknesses

  Medium- to long-term prospects remain uncertain following the termination of rocatinlimab development.

  Comparison

  One-month performance was +6.5%, outperforming TOPIX at +5.0% and the pharmaceutical sector at -5.6%.

  Risks

  Uncertainty remains regarding the timing and results of KHK4951 Phase 2 data disclosure.

• Sumitomo Pharma (4506)

  Weekly strong performer and event-tracking subject

  Strengths

  Rose 6.9% during June 15-19, the strongest weekly performer in the sample; the company disclosed the latest data on nuvisertib and enzomenib, while the approval-related event for Wegovy in MASH is also a focus.

  Weaknesses

  Medium- to long-term performance remains weak, with YTD performance of -36.6% and six-month performance of -35.9%.

  Comparison

  Led weekly performance relative to TOPIX but significantly lagged over the medium and long term.

  Risks

  Whether clinical assets deliver, products commercialize successfully, and the historically weak trend can reverse remains to be validated.

• Chugai Pharmaceutical (4519)

  Regulatory and product-event tracking subject

  Strengths

  The briefing on Elevidys, Japan's first DMD gene therapy, and the application for domestic manufacturing and marketing approval for sparsentan are event catalysts.

  Weaknesses

  Performance was negative over the one-month, three-month, six-month, and YTD periods.

  Comparison

  Weekly performance was +1.3%, below TOPIX at +4.2%; YTD performance was -8.4%.

  Risks

  Regulatory approval progress, product competition, and changes in prescription trends.

• Takeda Pharmaceutical (4502)

  Large pharmaceutical company and TRx tracking subject

  Strengths

  The report tracks US TRx data for Entyvio IV, Entyvio Pen, TAKHZYRO, VYVANSE, and other drugs, providing insight into commercialization trends.

  Weaknesses

  Weekly performance was -2.9%, one-month performance -6.1%, and three-month performance -14.5%.

  Comparison

  Short- and medium-term performance was weaker than TOPIX and some pharmaceutical peers.

  Risks

  Uncertainty regarding US prescription trends, competitive pressure, foreign exchange, and valuation recovery.

Key data

• Weekly Pharmaceutical Sector Performance+0.8% WoWDuring June 15-19, Japan's pharmaceutical sector rose 0.8%, underperforming TOPIX's +4.2%.
• Weekly TOPIX Performance+4.2%Risk appetite recovered during the period, but capital flowed mainly into AI- and semiconductor-related stocks.
• Sumitomo Pharma Weekly Performance+6.9%The largest weekly gain among the companies in the sample.
• Kyowa Kirin Weekly Performance+5.7%Outperformed TOPIX for the week and was also the sector's best performer over the past month.
• Kyowa Kirin One-Month Performance+6.5%TOPIX was +5.0% and the pharmaceutical sector was -5.6% over the same period.
• Pharmaceutical Sector Three-Month Performance-11.1%TOPIX was +12.1% over the same period, indicating significant sector underperformance.
• Pharmaceutical Sector Six-Month Performance-4.2%TOPIX was +19.5% over the same period.
• Pharmaceutical Sector YTD Performance-4.9%TOPIX was +18.7% over the same period.
• Key Clinical FocusKHK4951 Phase 2Kyowa Kirin's program for wet age-related macular degeneration and diabetic macular edema; the report expects the data may be disclosed at an academic conference in October.

Impact & implications

For investors, the report indicates that Japan's pharmaceutical sector remains relatively weak, and a recovery in broader-market risk appetite alone should not be taken as evidence of a simultaneous sector recovery. More important variables are whether company-specific catalysts materialize, including 2Q guidance, clinical data, regulatory approvals, major-drug TRx trends, and foreign-exchange effects. If events unfold smoothly in 2H 2026, some previously pressured stocks could see valuation and sentiment recoveries.

Risks

• Sector inflows may continue to be crowded out by strong-performing industries such as AI and semiconductors.
• Japan's pharmaceutical sector may continue to underperform TOPIX in the short term, and the weak trend may persist.
• Clinical trial data, academic conference disclosures, and regulatory approvals remain uncertain.
• Kyowa Kirin's medium- to long-term prospects remain uncertain following the termination of rocatinlimab development.
• The litigation between Nippon Shinyaku and Capricor Therapeutics concerning deramiocel could affect market sentiment.
• Exchange-rate movements may affect the profit performance of Japanese pharmaceutical companies.
• If US TRx prescription trends for major drugs fall below expectations, commercialization expectations for related companies may be pressured.

What to watch

• April-June results disclosures and management commentary on catalysts for the second half.
• The event and catalyst calendar for 2H 2026, particularly clinical and regulatory milestones for large pharmaceutical companies, mid-sized pharmaceutical companies, and biotechnology companies.
• Results from Kyowa Kirin's Phase 2 KHK4951 study and whether they will be disclosed at an academic conference in October.
• Further interpretation of Sumitomo Pharma's nuvisertib and enzomenib data.
• Chugai Pharmaceutical's Elevidys commercialization progress and sparsentan approval status.
• Market feedback following Santen Pharmaceutical's approval of Rhopressa in Japan.
• US TRx trends for major drugs from Takeda, Astellas, Chugai, Otsuka, Kyowa Kirin, Sumitomo Pharma, and other companies.
• Changes in the impact of foreign-exchange sensitivity on core operating profit, business profit, or earnings per share.